Literature DB >> 18287811

Integrin affinity modulation in angiogenesis.

Ganapati H Mahabeleshwar1, Juhua Chen, Weiyi Feng, Payaningal R Somanath, Olga V Razorenova, Tatiana V Byzova.   

Abstract

Integrins, transmembrane glycoprotein receptors, play vital roles in pathological angiogenesis, but their precise regulatory functions are not completely understood and remain controversial. This study aims to assess the regulatory functions of individual beta subunits of endothelial integrins in angiogenic responses induced by vascular endothelial growth factor (VEGF). Inhibition of expression of beta(1), beta(3), or beta(5) integrins in endothelial cells resulted in down regulation of EC adhesion and migration on the primary ligand for the corresponding integrin receptor, while no effects on the recognition of other ligands were detected. Although inhibition of expression of each subunit substantially affected capillary growth stimulated by VEGF, the loss of beta(3) integrin was the most inhibitory.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18287811      PMCID: PMC2677212          DOI: 10.4161/cc.7.3.5234

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  51 in total

Review 1.  Ligand binding to integrins.

Authors:  E F Plow; T A Haas; L Zhang; J Loftus; J W Smith
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

2.  A mechanism for modulation of cellular responses to VEGF: activation of the integrins.

Authors:  T V Byzova; C K Goldman; N Pampori; K A Thomas; A Bett; S J Shattil; E F Plow
Journal:  Mol Cell       Date:  2000-10       Impact factor: 17.970

3.  Integrin-mediated death: an explanation of the integrin-knockout phenotype?

Authors:  David A Cheresh; Dwayne G Stupack
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

Review 4.  A reevaluation of integrins as regulators of angiogenesis.

Authors:  Richard O Hynes
Journal:  Nat Med       Date:  2002-09       Impact factor: 53.440

Review 5.  Coming to grips with integrin binding to ligands.

Authors:  M Amin Arnaout; Simon L Goodman; Jian-Ping Xiong
Journal:  Curr Opin Cell Biol       Date:  2002-10       Impact factor: 8.382

6.  Molecular mechanisms underlying the proangiogenic effect of factor XIII.

Authors:  Rima Dardik; Joseph Loscalzo; Regina Eskaraev; Aida Inbal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-12-23       Impact factor: 8.311

Review 7.  Integrin and growth factor receptor crosstalk.

Authors:  B P Eliceiri
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

8.  Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins.

Authors:  Louise E Reynolds; Lorenza Wyder; Julie C Lively; Daniela Taverna; Stephen D Robinson; Xiaozhu Huang; Dean Sheppard; Richard O Hynes; Kairbaan M Hodivala-Dilke
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

9.  Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain.

Authors:  E Borges; Y Jan; E Ruoslahti
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

Review 10.  GPR56 and TG2: possible roles in suppression of tumor growth by the microenvironment.

Authors:  Lei Xu; Richard O Hynes
Journal:  Cell Cycle       Date:  2007-01-28       Impact factor: 4.534

View more
  37 in total

1.  Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin αvβ₃.

Authors:  Sribalaji Lakshmikanthan; Magdalena Sobczak; Changzoon Chun; Angela Henschel; Jillian Dargatz; Ramani Ramchandran; Magdalena Chrzanowska-Wodnicka
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

Review 2.  Signal transduction by vascular endothelial growth factor receptors.

Authors:  Sina Koch; Lena Claesson-Welsh
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  Unique disulfide bonds in epidermal growth factor (EGF) domains of β3 affect structure and function of αIIbβ3 and αvβ3 integrins in different manner.

Authors:  Ronit Mor-Cohen; Nurit Rosenberg; Yulia Einav; Ehud Zelzion; Meytal Landau; Wissam Mansour; Yulia Averbukh; Uri Seligsohn
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

4.  Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential.

Authors:  Radu Minea; Corey Helchowski; Barbara Rubino; Kyle Brodmann; Stephen Swenson; Francis Markland
Journal:  Toxicon       Date:  2011-02-24       Impact factor: 3.033

5.  A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling.

Authors:  Adam C Mirando; Jikui Shen; Raquel Lima E Silva; Zenny Chu; Nicholas C Sass; Valeria E Lorenc; Jordan J Green; Peter A Campochiaro; Aleksander S Popel; Niranjan B Pandey
Journal:  JCI Insight       Date:  2019-02-21

6.  Optogenetic interrogation of integrin αVβ3 function in endothelial cells.

Authors:  Zhongji Liao; Ana Kasirer-Friede; Sanford J Shattil
Journal:  J Cell Sci       Date:  2017-09-01       Impact factor: 5.285

7.  Dual regulation of Stat1 and Stat3 by the tumor suppressor protein PML contributes to interferon α-mediated inhibition of angiogenesis.

Authors:  Kuo-Sheng Hsu; Xuan Zhao; Xiwen Cheng; Dongyin Guan; Ganapati H Mahabeleshwar; Yu Liu; Ernest Borden; Mukesh K Jain; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

8.  alpha5beta1 Integrin blockade inhibits lymphangiogenesis in airway inflammation.

Authors:  Tatsuma Okazaki; Amy Ni; Oluwasheyi A Ayeni; Peter Baluk; Li-Chin Yao; Doerte Vossmeyer; Gunther Zischinsky; Grit Zahn; Jochen Knolle; Claudia Christner; Donald M McDonald
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

9.  Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities.

Authors:  Radu O Minea; Corey M Helchowski; Samuel J Zidovetzki; Fritz K Costa; Stephen D Swenson; Francis S Markland
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

10.  Clinically relevant doses of candesartan inhibit growth of prostate tumor xenografts in vivo through modulation of tumor angiogenesis.

Authors:  Ahmed Alhusban; Ahmad Al-Azayzih; Anna Goc; Fei Gao; Susan C Fagan; Payaningal R Somanath
Journal:  J Pharmacol Exp Ther       Date:  2014-07-02       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.